Similar articles

• Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study.

  Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, Edwards VM, Werch J. Aach RD, et al. N Engl J Med. 1981 Apr 23;304(17):989-94. doi: 10.1056/NEJM198104233041701. N Engl J Med. 1981. PMID: 6782484
• Posttransfusion hepatitis: clinical features, risk and donor testing.

  Alter HJ. Alter HJ. Prog Clin Biol Res. 1985;182:47-61. Prog Clin Biol Res. 1985. PMID: 3929262 Review. No abstract available.
• Post-transfusion hepatitis and serum alanine aminotransferase in blood donors.

  [No authors listed] [No authors listed] N Engl J Med. 1981 Aug 13;305(7):403-4. doi: 10.1056/NEJM198108133050713. N Engl J Med. 1981. PMID: 6789203 No abstract available.
• [Currently available means for the prevention of post-transfusion hepatitis and criteria for their application].

  Bedarida G, Cambiè G, D'Agostino F, Sterza G. Bedarida G, et al. Ric Clin Lab. 1984;14 Suppl 1:37-60. Ric Clin Lab. 1984. PMID: 6429830 Review. Italian. No abstract available.
• Based on your analysis of the benefits and costs of routine donor screening for ALT-GPT to reduce the incidence of post-transfusion non-A, non-B hepatitis in your blood services region, what action would you recommend on this matter?

  [No authors listed] [No authors listed] Vox Sang. 1983;44(1):48-64. Vox Sang. 1983. PMID: 6402857 No abstract available.